文献速递胸部肿瘤放疗放疗物理与技术

放疗联合厄洛替尼对非小细胞肺癌患者肺部18F-FDG摄取及细胞因子谱的影响

Assessment of pulmonary 18F-FDG-PET uptake and cytokine profiles in non-small cell lung cancer patients treated with radiotherapy and erlotinib.
PubMed 文献 · Clin Transl Radiat Oncol · 2017-06-15

结果显示联合治疗组治疗后肺部未照射区域葡萄糖摄取(SUV0)显著升高,且与血清CCL21水平正相关。

要点

  • 放疗联合厄洛替尼组治疗后SUV0较治疗前升高58%,较治疗中期升高45%。
  • 联合治疗组治疗后SUV0较单纯放疗组高42%。
  • 联合治疗组SUV0与血清CCL21水平呈正相关(r=0.47,P=0.01)。

核心结论

  • 放疗联合厄洛替尼较单纯放疗导致治疗后肺部18F-FDG摄取升高。
  • 肺部葡萄糖摄取与炎症相关趋化因子CCL21上调相关。

研究设计与样本

  • 治疗前、治疗中及治疗后共分析57次18F-FDG PET扫描,并采用多路生物测定法检测血清细胞因子。

主要发现

  • 联合治疗组治疗后SUV0显著高于治疗前(升高58%)和治疗中期(升高45%),P<0.001。
  • 联合治疗组治疗后SUV0较单纯放疗组高42%(P<0.001)。
  • ΔSUV在不同治疗或时间点间无差异。
  • 联合治疗组SUV0与血清CCL21水平正相关(r=0.47,P=0.01)。

临床怎么用

  • 放疗联合厄洛替尼治疗非小细胞肺癌时,需关注治疗后肺部未照射区域18F-FDG摄取升高,可能反映炎症反应。
  • 血清CCL21水平或可作为肺部葡萄糖摄取升高的相关生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate effects of radiotherapy (RT) and erlotinib on pulmonary glucose uptake using 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) positron emission tomography (PET) during and after treatment of non-small cell lung cancer (NSCLC) and to identify associations between serum cytokine levels and lung glucose uptake. MATERIAL AND METHODS: Twenty-seven patients with advanced NSCLC, receiving RT alone or concomitant RT and erlotinib therapy, were examined by 18F-FDG PET before, during, and after treatment. A total of 57 18F-FDG PET scans were analyzed. Pulmonary 18F-FDG uptake and radiotherapy dose mapping were used to acquire dose-response curves for each patient, where subsequent linear regression gave a glucose uptake level in the un-irradiated parts of the lungs (SUV0) and a response slope (ΔSUV). Serum cytokine levels at corresponding time points were assessed using a multiplex bioassay. Correlations between the most robust cytokines and lung 18F-FDG dose response parameters were further investigated. RESULTS: From the dose response analysis, SUV0 at post-therapy was significantly higher (P < 0.001) than at mid- and pre-therapy (45% and 58%, respectively) for the group receiving RT + erlotinib. Also, SUV0 at post-therapy was higher for patients receiving RT + erlotinib compared to RT alone (42%; P < 0.001). No differences in ΔSUV were seen with treatments or time. SUV0 was positively associated (r = 0.47, P = 0.01) with serum levels of the chemokine C-C motif ligand 21 (CCL21) for patients receiving RT + erlotinib. CONCLUSIONS: Concomitant RT and erlotinib causes an elevation in pulmonary 18F-FDG uptake post treatment compared to RT alone. Pulmonary glucose uptake is associated with an upregulation of a chemokine (CCL21) involved in inflammatory reactions.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Abravan A, Eide HA, Knudtsen IS, et al. Assessment of pulmonary 18F-FDG-PET uptake and cytokine profiles in non-small cell lung cancer patients treated with radiotherapy and erlotinib. Clin Transl Radiat Oncol. 2017. PMID: 29594209. doi:10.1016/j.ctro.2017.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。